Infliximab Monoclonal Antibody from China
Infliximab (Remicade) is a chimeric monoclonal antibody neutralizing TNF-alpha for Crohn's disease and psoriasis. Classifies in HTS 3002.13.0010 for unmixed monoclonal immunological products from biotech, aligning with chapter's peptide/protein definition. Bulk for further processing.
Duty Rate — China → United States
100%
Rate breakdown
9903.04.60100%Pharmaceuticals: patented pharma articles — 100% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Document GMP compliance from EU or other certified facilities for faster release
• Test for immunogenicity profiles in COA to support therapeutic claims
• Avoid bulk packaging resembling retail to prevent 3002.15 reclassification